Sign in
CompletedNo phase

A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients

Key facts

Who runs it
Rose Pharma SA
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
47 people enrolled
Started
24 Jul 2024
Ended
8 Aug 2025
Type of study
Interventional
Treatments tested
  • Syrup made by hyaluronic acid
Record updated
4 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patient who signed Informed consent form
  • Male or Female over 18 years old at the time of the signature of the Informed consent form
  • Symptomatic non-erosive reflux disease (heartburn and/or regurgitation) for at least 8 weeks
  • RDQ (Reflux Disease Questionnaire) score ≥ 12 at baseline (questionnaire specific for reporting the frequency and severity of upper gastrointestinal symptoms)
  • Willingness to follow all study procedures, including attending all site visits, tests and examinations

Who cannot take part

  • Use of proton pump inhibitors or H2 receptor antagonists in the previous 4 weeks
  • Simultaneous participation in an interventional study or participation in an interventional study in the last 1 month before study inclusion
  • Known drug and/or alcohol abuse
  • Diagnosis of Helicobacter pylori infection
  • Uncontrolled cardiac, renal, liver or pulmonary disease
  • Diabetes
  • Active malignant neoplasia
  • Known allergy to device components
  • Esophagitis according to the Los Angeles classification (grade A to D)
  • Pregnancy or breast-feeding
  • Mental incapacity that precludes adequate understanding or cooperation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study involves a medical device in the form of syrup, not yet on the market and tested for the first time in humans, named "FIBROIN SYRUP". The intended use is to reduce the GastroEsophageal Reflux Disease (GERD) symptoms such as heartburn, epigastric pain, irritative and nocturnal cough, dysphagia and dysphonia, which may occur especially after meals or during the night due to lying position. "FIBROIN SYRUP" has never been tested on humans and this study aims to evaluate the safety, tolerability and efficacy of the medical device when taken after the main meals (breakfast, lunch, and dinner; total: 3 sticks/day) for 6 weeks.

The group in the trial

  • Adult patients suffering from gastroesophageal reflux diseaseTreatment being tested

    Treatment: Syrup made by hyaluronic acid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 May 2026